Essex Woodlands Management’s Ligand Pharmaceuticals LGND Stock Holding History

Essex Woodlands Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-49,687	Closed	-$3.28M	–	10
2017 Q1	$3.28M	Sell	49,687 -3,040	-6%	-$200K	0.75%	8
2016 Q4	$2.42M	Hold	52,727	–	–	0.55%	8
2016 Q3	$2.4M	Hold	52,727	–	–	0.5%	9
2016 Q2	$3.92M	Buy	+52,727	New	+$3.91M	0.99%	8

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Essex Woodlands Management's LGND Position: Q2 2017 in Review

Essex Woodlands Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2017, closing a stake of 49,687 shares — an estimated $3.28M sold.

Essex Woodlands Management first reported a position in LGND in Q2 2016 and held it in 4 quarters. The position peaked at $3.92M in Q2 2016. 266 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

Essex Woodlands Management reported no remaining Ligand Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Essex Woodlands Management sold 49,687 Ligand Pharmaceuticals shares in Q2 2017, an estimated $3.28M.
Essex Woodlands Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 4 quarters.
Essex Woodlands Management's Ligand Pharmaceuticals position peaked at $3.92M in Q2 2016.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Essex Woodlands Management's 13F filing for Q2 2017, filed 14 Aug 2017.